Incorporating composite scoring schema (e.g. GALAD and BALAD scores), and incorporating novel biomarkers such as GPC3 and SALL4, have shown promise in the diagnosis and prognostication of HCC. The gene discussed is SALL4; the disease is hepatocellular carcinoma.